Translating monotherapy trials into clinical practice: A look into the abyss

Epilepsy and Behavior

Volumn 4, Issue 5, 2003, Pages 457-463

  Arroyo, Santiago ^a   Perucca, Emilio ^b  

^a FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Anticonvulsants; Antiepileptic drugs; Clinical trials; Monotherapy; Polytherapy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; NEW DRUG; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; REMACEMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AGE DISTRIBUTION; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DATA ANALYSIS; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG APPROVAL; DRUG INFORMATION; DRUG LABELING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EPILEPSY; FOCAL EPILEPSY; HUMAN; MAINTENANCE THERAPY; METHODOLOGY; MONOTHERAPY; PARESTHESIA; POSTMARKETING SURVEILLANCE;

EID: 0242522185     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yebeh.2003.07.011     Document Type: Article

References (29)

1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9.
2. Perucca E. Pharmacologic advantages of antiepileptic drug monotherapy. Epilepsia 1997;38(Suppl. 5):6-8.
3. Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003;60(11, Suppl. 4):S2-S12.
4. Gilliam FG. Limitations of monotherapy trials in epilepsy. Neurology 2003;60(11, Suppl. 4):S26-30.
5. Food and Drug Administration (FDA).Guidance for industry: clinical evaluation af antiepileptic drugs (in adults and children). FDA; 1997.
6. European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Note for guidance on clinical investigation of medicinal products in the treatment of epileptic disorders. http://www.health.gov.au/tga/ docs/pdf/euguide/ewp/056698en.pdf. 2001.
7. French JA, Schachter S. A workshop on antiepileptic drug monotherapy indications. Epilepsia 2002;43(Suppl. 10):3-27.
8. Brodie MJ, Bomhof MAM, Kälviäinen R. Double-blind comparison of tiagabine and carbamazepine monotherapy in newly diagnosed epilepsy (abstract). Epilepsia 1997;38(Suppl. 3):66.
9. Chadwick DW, Betts TA, Boddie HG, et al. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen. Seizure 2002;11:114-23.
10. Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJS. Vigabatrin vs. carbamazepine monotherapy in patients with newly diagnosed epilepsy: a randomized, controlled study. Arch Neurol 1995;52:989-96.
11. Chadwick DG. Vigabatrin European Monotherapy Study Group. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 1999;354:13-9.
12. Gilliam FG, Veloso F, Bomhof MA, et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003;60:196-202.
13. Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol 2001;15:405-17.
14. World Medical Association. Declaration of Helsinki (as revised). http://www.wma.net/e/policy/b3.htm.
15. Leber P. Hazards of inference: The active control investigation. Epilepsia 1989;30(Suppl. 1):S57-63.
16. Beydoun A, Kutluay E. Adjunctive clinical trials in epilepsy: is a placebo arm necessary? Epilepsy Behav 2003;4:4-5.
17. Perucca E. Innovative monotherapy trial designs for the assessment of antiepileptic drugs: a critical appraisal. Eur J Clin Pharmacol 1998;54:1-6.
18. Perucca E, Tomson T. Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res 1999;33:247-62.
19. Beydoun A, Kutluay E. Conversion to monotherapy: clinical trials in patients with refractory partial seizures. Neurology 2003;60(Suppl. 4):S13-25.
20. Karlawish JH, French J. The ethical and scientific shortcomings of current monotherapy epilepsy trials in newly diagnosed patients. Epilepsy Behav 2001;2:193-200.
21. French JA. Active-control antiepileptic drug trials in the newly diagnosed patient: are we getting closer? Epilepsy Behav 2002;3:109-12.
22. Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998;51:1018-25.
23. Arroyo S, Elger C, Russi A, et al. Short-term intravenous adjunctive therapy of MHD inpatients with refractory partial seizures undergoing presurgical evaluation (abstract). Epilepsia 2000;41(Suppl. 7):101.
24. Arroyo S, Squires L, Wang S, Twyman RE. Topiramate: effective as monotherapy in dose-response study in newly diagnosed epilepsy (abstract). Epilepsia 2002;43(Suppl. 7):241.
25. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. EPMN 105 Study Group. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107:165-75.
26. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995;345(8948):476-9.
27. Beydoun A, Milling CJ. Active-control comparative equivalency monotherapy trials in epilepsy: are they scientifically valid? Epilepsy Behav 2001;2:187-92.
28. Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002;43:993-1000.
29. Arroyo S, Sander JW. Carbamazepine in comparative trials: pharmacokinetic characteristics too often forgotten. Neurology 1999;53:1170-4.